To analyze the therapeutic effect of mifepristone, misoprostol and curettage on embryo development. Methods: 56 patients with embryonic development arrest diagnosed and treated in our hospital from March 2019 to March...To analyze the therapeutic effect of mifepristone, misoprostol and curettage on embryo development. Methods: 56 patients with embryonic development arrest diagnosed and treated in our hospital from March 2019 to March 2021 were selected as observation objects, and were divided into two groups according to different treatment plans. The reference group and the research group were treated with misoprostol combined with curettage, mifepristone and misoprostol combined with curettage respectively. The effects of cervical softening and dilation, success rate of one-time curettage, operation index, incidence of adverse reactions and the effects on the levels of immune function index, D- dimer and three items of thyroid function of patients in the two groups were compared. Results: compared with the reference group, the total effective rate of cervical softening and dilation in the study group was 96.43%, the success rate of one-time curettage was 100.00% higher, the time of operation, pregnancy discharge and vaginal hemorrhage were shorter, the amount of intraoperative hemorrhage was less, the levels of immune function indexes (IgA, IgM, IgG) were higher, and the values of three indexes of three items of thyroid function (TSH, FT3, FT4) and D- dimer were lower in the study group, P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: the combined use of mifepristone, misoprostol and curettage in patients with embryonic development arrest has significant effects on improving the cervical softening and dilation effect, increasing the success rate of one-time curettage and improving the operation condition of patients, immune function after treatment, D- dimer and three indexes of hypothyroidism.展开更多
文摘To analyze the therapeutic effect of mifepristone, misoprostol and curettage on embryo development. Methods: 56 patients with embryonic development arrest diagnosed and treated in our hospital from March 2019 to March 2021 were selected as observation objects, and were divided into two groups according to different treatment plans. The reference group and the research group were treated with misoprostol combined with curettage, mifepristone and misoprostol combined with curettage respectively. The effects of cervical softening and dilation, success rate of one-time curettage, operation index, incidence of adverse reactions and the effects on the levels of immune function index, D- dimer and three items of thyroid function of patients in the two groups were compared. Results: compared with the reference group, the total effective rate of cervical softening and dilation in the study group was 96.43%, the success rate of one-time curettage was 100.00% higher, the time of operation, pregnancy discharge and vaginal hemorrhage were shorter, the amount of intraoperative hemorrhage was less, the levels of immune function indexes (IgA, IgM, IgG) were higher, and the values of three indexes of three items of thyroid function (TSH, FT3, FT4) and D- dimer were lower in the study group, P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: the combined use of mifepristone, misoprostol and curettage in patients with embryonic development arrest has significant effects on improving the cervical softening and dilation effect, increasing the success rate of one-time curettage and improving the operation condition of patients, immune function after treatment, D- dimer and three indexes of hypothyroidism.
